Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
Closed Posted
- Opportunity number
- RFA-CA-25-001
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Up to $150,000
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Categories
-
- Education
- Health
- Eligible applicants
-
- County Governments
- Non-501(c)(3) Nonprofits
- For Profit Organizations
- Higher Education Inst. (Public)
- City/Township Governments
- Small Businesses
- State Governments
- Tribal Organizations (Not Federally Recognized)
- Higher Education Inst. (Private)
- 501(c)(3) Nonprofits
- Public or Indian Housing Auth.
- Independent School Districts
- Tribal Governments (Federally Recognized)
- Other
- Special District Governments
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Cancer Institute (NCI) is seeking grant applications for early-stage development of innovative molecular and cellular analysis technologies specifically focused on cancer research. This funding opportunity, part of the Innovative Molecular Analysis Technologies (IMAT) Program, aims to support the creation of novel technological capabilities for targeting, probing, and assessing molecular and cellular features of cancer biology. Eligible applicants include county and city governments, nonprofits, for-profit organizations, higher education institutions, small businesses, state governments, and tribal organizations. Proposed technologies must demonstrate high technical innovation and potential to accelerate or enhance research in areas such as cancer biology, early detection, clinical diagnosis, treatment, and epidemiology. The grant opportunity (RFA-CA-25-001) has a due date of December 9, 2025, and will utilize the R61 grant mechanism, with the explicit requirement that proposed projects cannot include clinical trials.
While specific award amounts are not detailed in the documentation, the grant is part of the Cancer Detection and Diagnosis Research program (CFDA 93.394), which typically funds projects ranging from $200,000 to nearly $3 million. The project period is expected to support early-stage technology development, with research to be conducted at the recipient's facilities across the United States. The NCI emphasizes that while proposed technologies may have broad potential applications, they must specifically target improvements in molecular and cellular characterization of cancer biology, with a particular focus on addressing potential cancer health disparities or providing significant research advancements in cancer-related scientific understanding.
Synopsis
2 versions
Update #2 · Latest ·
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this NOFO is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, or epidemiology, and/or address issues associated with cancer health disparities.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Update #1 ·
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this NOFO is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, or epidemiology, and/or address issues associated with cancer health disparities. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Files
| File | Type | Posted |
|---|---|---|
| RFA-CA-25-001-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity